WHO: Europe's vaccine rollout unacceptably slowEuropost
The World Health Organisation (WHO) criticised the rollout of coronavirus vaccines in Europe as being "unacceptably slow", news wires reported. "Vaccines present our best way out of this pandemic... However, the rollout of these vaccines is unacceptably slow and is prolonging the pandemic in the wider Europe region,” WHO director for Europe Hans Kluge said in a statement.
"We must speed up the process by ramping up manufacturing, reducing barriers to administering vaccines, and using every single vial we have in stock, now," he added. In the meantime, as long as vaccine coverage remained low, he said EU countries would have to impose lockdowns and other measures to compensate for the delays. Kluge also warned that the vaccine rollout, despite its slow speed, risked "providing a false sense of security to authorities and the public alike".
Last week saw increasing transmission of Covid-19 in the majority of countries in the WHO European region - which includes more than 50 countries and extends from Greenland to the far east of Russia. There were 1.6 million new cases and close to 24,000 deaths, the WHO said. Only 10% of the nearly 900 million people in the region have had a single dose of coronavirus vaccine so far.
It remains the second most affected by the virus of all the world's regions, with the total number of deaths fast approaching one million and the total number of cases about to surpass 45 million, it added. The WHO also warned of the risks of greater spread associated with increased mobility and number of gatherings over the forthcoming religious holidays of Passover, Easter and Ramadan.
Only 16% of the EU's population has so far received a dose of vaccine. The EU was slow to negotiate a contract with vaccine manufacturer AstraZeneca which caused supply problems. It also sparked a political row with the UK, where AstraZeneca has plants and where 52% of the population has had at least one dose. The EU's deals with Pfizer-BioNTech and Moderna also ran into early problems with production and distribution.
EU regulators were then slow to authorise vaccines for use. Some EU countries subsequently paused their rollouts of the AstraZeneca jab over reports of blood clots among a small number of people who had received a dose. Others restricted its use among older people over concerns that the company had not provided enough testing data.